Research Study

 
News Articles for Research Study top ^
Latest Data Sweep from Large Subgroup of Patients Shows a Strong 50% Improvement in Overall Survival for ThermoDox® Pisa University's Professor Riccardo Lencioni Highlights HEAT Study Post-Hoc Analysis, Rationale for the Phase III OPTIMA Study LAWRENCEVILLE, N.J. , April 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review of the final study design of the Phase III OPTIMA Study, which both explore ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer, were presented at the 5 th European Conference on Interventional Oncology (ECIO) on April 24, 2014 in Berlin , Germany.
Sign-up for Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014 investment picks
- On Track for Study Participation in Major HCC Markets Worldwide - LAWRENCEVILLE, N.J. , May 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan , Hong Kong , South Korea and Canada.
Sign-up for Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer investment picks
2014/5/14
Financial Advisor Retained to Arrange Project Debt Facility Shares Issued and Outstanding: 106,039,522 TSX: MPV NYSE MKT: MDM TORONTO AND NEW YORK , May 14, 2014 /PRNewswire/ - Mountain Province Diamonds Inc. ("Mountain Province", the "Company") (TSX: MPV, NYSE MKT: MDM) today announced that the Gahcho Kué Project - 2014 Feasibility Study Report has been filed and will be available on SEDAR, EDGAR and the Company's website.
Sign-up for Mountain Province Diamonds Files Gahcho Kué Project, 2014 Feasibility Study Report investment picks
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - NEW HAVEN, Conn., April 30, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that is has begun dosing study participants with ACH-3422, Achillion's proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial.
Sign-up for Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV investment picks
2014/4/28
First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 volunteers from Asia  Initial safety data are consistent with the good safety profile observed in previous studies   LYON, France, April 28, 2014 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the first of two pivotal Phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint.
Sign-up for The World's First, Large-Scale Dengue Vaccine Efficacy Study Successfully Achieved Its Primary Clinical Endpoint investment picks
Study demonstrates that investments in network quality do translate into better financial returns for operators, not only from cost savings but also from increased revenue Study shows network investments generate 5.5 percent increase in service revenues and a 6.4 percent improvement of EBITDA margin in a case of a 10% increase in capital expenditure for an operator in Brazil Decrease of 1 percentage point in overall churn leads to a 6.86 percent increase in service revenues STOCKHOLM, Sweden, May 7, 2014 (GLOBE NEWSWIRE) -- A new study commissioned by Ericsson (NASDAQ:ERIC) shows that increased level of investments in network quality and performance create sustainable competitive advantages and improved financial returns for network operators.
Sign-up for Study: Capital investment improves network performance, giving better returns investment picks
NEWARK, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) , today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines.
Sign-up for Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines investment picks
- Top-line Efficacy Data Expected in 3Q14 - NDA filing expected in 2H15 SALT LAKE CITY, April 29, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN) , a specialty pharmaceutical company, today announced that the Company has completed enrollment of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study ( http://clinicaltrials.gov/show/NCT02081300 ). The trial is designed to evaluate the safety and efficacy of LPCN 1021, oral testosterone undecanoate ("TU"), in hypogonadal men with low testosterone ("Low T"). The Company expects top-line efficacy data for the trial to be available in the third quarter of 2014, with a New Drug Application ("NDA") filing with the U.S. Food and Drug Administration ("FDA") anticipated in the second half of 2015.
Sign-up for Lipocine Announces Completion of Enrollment in its SOAR Phase 3 Study for Oral Testosterone Replacement Therapy investment picks
NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas.
Sign-up for Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Advanced Gynecologic Malignancies (SIGN Study) investment picks
2014/4/29
Results presented at the American Academy of Neurology meeting On track to initiate Phase 3 study in infants with SMA mid-year On track to initiate Phase 3 study in children with SMA in the second half of the year Isis to host an investor event and live webcast at 6:00 p.m. EDT on Tuesday, April 29 in Philadelphia CARLSBAD, Calif.
Sign-up for Isis Reports Updated Results from ISIS-SMN Rx Clinical Studies in Infants and Children with Spinal Muscular Atrophy investment picks
2014/5/1
Capstone Files Technical Report for Pinto Valley Pre-Feasibility Study Canada NewsWire VANCOUVER , May 1, 2014 /CNW/ - Capstone Mining Corp.
Sign-up for Capstone Files Technical Report for Pinto Valley Pre-Feasibility Study investment picks
VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP) , a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study in progress" poster on the FLAGSHIP trial of its lead development candidate, AQX-1125, at the 2014 American Thoracic Society (ATS) International Conference.
Sign-up for Corrected - Aquinox Pharmaceuticals Announces Presentation on FLAGSHIP Study at the 2014 American Thoracic Society International Conference investment picks
VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP) , a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study in progress" poster on the FLAGSHIP trial of its lead development candidate, AQX-1125, at the 2014 American Thoracic Society (ATS) International Conference.
Sign-up for Aquinox Pharmaceuticals Announces Presentation on FLAGSHIP Study at the 2014 American Thoracic Society International Conference investment picks
2014/5/14
Alaska Airlines Mileage Plan also receives top ranking in inaugural airline loyalty satisfaction report SEATTLE , May 14, 2014 /PRNewswire/ -- Alaska Airlines ranked highest in airline customer satisfaction among traditional carriers for the seventh consecutive year in the J.D. Power 2014 North America Airline Satisfaction Study SM .
Sign-up for J.D. Power Study Ranks Alaska Airlines Highest in Traditional Carrier Satisfaction for Seventh Straight Year investment picks
2014/5/21
Free Download with 94 Charts and 29 Pages of Objective Analyses JACKSONVILLE, Fla.
Sign-up for MarketingSherpa E-commerce Benchmark Study Reveals How 4,346 E-commerce Marketers Define, Drive Success investment picks
Organizations face IT infrastructure challenges around the growth of cloud, analytics, social and mobile LAS VEGAS , May 19, 2014 /PRNewswire/ -- Less than ten percent of organizations say their existing IT infrastructure is fully prepared to address the proliferation of mobile devices , social media , data analytics and cloud computing , according to preliminary findings released today by IBM (NYSE: IBM ). The forthcoming study, titled "IT Infrastructure Matters," is based on responses from 750 CTOs, CIOs and other technology executives in 18 countries and 19 industries.
Sign-up for IBM Study: Organizations Unprepared to Tackle Next Wave of Technology Trends investment picks
BURLINGTON, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO) today announced that an Investigator-Initiated Study evaluating TSO ( Trichuris suis ova or CNDO-201) for the treatment of pediatric patients with autism spectrum disorder (ASD) has initiated.
Sign-up for Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Pediatric Patients With Autism Spectrum Disorder investment picks
SOUTH SAN FRANCISCO, Calif., April 14, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.
Sign-up for Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Storage  |  Next: Research Subscription